Last update 21 Dec 2024
JPB-898
Last update 21 Dec 2024
Overview
Basic Info
Drug Type Biosimilar, Monoclonal antibody |
Synonyms Nivolumab Biosimilar (Sandoz Group AG), JPB-898 |
Target |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Gene Sequence
Sequence Code 93681H
The sequence is quoted from: *****
Sequence Code 93684L
The sequence is quoted from: *****
Related
2
Clinical Trials associated with JPB-898A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of JPB898 (proposed Nivolumab Biosimilar) and US-licensed and EU-authorized Opdivo® in Combination with Yervoy® in Participants with Untreated Advanced (unresectable/metastatic) Melanoma
A Multi-center, Open-label Study to Assess the Safety and Efficacy of Combination Ceritinib (LDK378) and Nivolumab in Adult Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC)
100 Clinical Results associated with JPB-898
Login to view more data
100 Translational Medicine associated with JPB-898
Login to view more data
100 Patents (Medical) associated with JPB-898
Login to view more data
100 Deals associated with JPB-898
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Melanoma | Phase 3 | - | 01 Jan 2025 | |
| ALK positive Non-Small Cell Lung Cancer | Phase 1 | US | 27 May 2015 | |
| ALK positive Non-Small Cell Lung Cancer | Phase 1 | AU | 27 May 2015 | |
| ALK positive Non-Small Cell Lung Cancer | Phase 1 | BE | 27 May 2015 | |
| ALK positive Non-Small Cell Lung Cancer | Phase 1 | CA | 27 May 2015 | |
| ALK positive Non-Small Cell Lung Cancer | Phase 1 | HK | 27 May 2015 | |
| ALK positive Non-Small Cell Lung Cancer | Phase 1 | IT | 27 May 2015 | |
| ALK positive Non-Small Cell Lung Cancer | Phase 1 | SG | 27 May 2015 | |
| ALK positive Non-Small Cell Lung Cancer | Phase 1 | ES | 27 May 2015 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free